Comparative Pharmacology
Head-to-head clinical analysis: OXYCODONE 5 APAP 500 versus WESTADONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OXYCODONE 5 APAP 500 versus WESTADONE.
OXYCODONE 5/APAP 500 vs WESTADONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Oxycodone: mu-opioid receptor agonist; Acetaminophen: cyclooxygenase (COX) inhibition, analgesic and antipyretic via central action.
Mu-opioid receptor agonist; also acts as an NMDA receptor antagonist and inhibits serotonin and norepinephrine reuptake.
1-2 tablets (oxycodone 5-10 mg/APAP 500-1000 mg) orally every 4-6 hours as needed for pain; maximum APAP dose 4000 mg/day from all sources.
Oral: 2.5-10 mg every 4-6 hours as needed for pain; maximum 40 mg per day.
None Documented
None Documented
Oxycodone: Terminal half-life 3.5-5.6 hours (mean 4.5 h); prolonged in renal/hepatic impairment. Acetaminophen: 2-3 hours.
Terminal elimination half-life: 15-60 hours (mean ~24 hours). Clinical context: Prolonged half-life supports once-daily dosing in opioid maintenance; accumulation occurs with repeated dosing due to long half-life.
Renal: Oxycodone ~87% (10% unchanged, 77% as metabolites); Acetaminophen ~85% (2-5% unchanged, rest as glucuronide and sulfate conjugates). Biliary/fecal: Minimal for both.
Primarily renal (40-50% as unchanged methadone and its metabolites, 15-20% as metadone-N-oxide), biliary/fecal (5-10%).
Category D/X
Category C
Opioid Agonist
Opioid Agonist